Immuno modulator-1
Immuno modulator-1 (compound 22) inhibits TNFα and IL-2 secretion in human peripheral blood mononuclear cells (hPBMC), with IC50 values of 4.7 and 26 nM, respectively. Immuno modulator-1 shows hERG potassium channel blocking effect, with Inhibitory percentage of 20% at 3 μM.
For research use only. We do not sell to patients.
- CAS No.: 2757469-20-6
- Formula: C32H31FN6O4
- Molecular Weight:582.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
IL-2 |
In Vitro
Immuno modulator-1 (compound 22) inhibits the proliferation of NCI-H929 human myeloma cell, with an IC50 of 0.6 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats[1]
-
Dosage:1 mg/kg (IV), 5 mg/kg (PO)
-
Administration:IV (2 mL/kg), PO (10 mL/kg); once (Pharmacokinetic Analysis)
-
Result:Pharmacokinetic Parameters of Immuno modulator-1 in male Sprague-Dawley rats[1].
IV (1 mg/kg) PO (5 mg/kg) Cmax (ng/mL) 1437 AUC0-24 (ng/mL∗h) 13029 CL (mL/min/kg) 2.2 Vss (L/kg) 0.36 F (%) 30%
Chemical Information
-
CAS No. 2757469-20-6
-
Molecular Weight 582.62
-
Formula C32H31FN6O4
-
SMILES
C[C@@H](N1CCN(C2=C(C=C(C=N2)C#N)F)CC1)C(C=C3)=CC=C3COC4=C5C(C(N([C@@H]6C(NC(CC6)=O)=O)C5)=O)=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
PBMC Thawing for Immune Assays
PBMC thawing for immune assays recovers viable cryopreserved peripheral blood mononuclear cells for downstream functional or phenotypic readouts, including ELISPOT, intracellular cytokine staining, proliferation assays, and flow-cytometric immunophenotyping. Cryopreserved PBMCs can support immune monitoring because antigen-specific T-cell function and major CD4/CD8 phenotypes may be retained after optimized freezing and thawing, although some lymphocyte subsets and activation or memory markers can be altered by cryopreservation. The technical objective is rapid warming of the frozen vial followed by controlled dilution and removal of DMSO-containing cryomedium, because thawing and wash conditions measurably affect viable PBMC recovery and downstream assay performance. Viability alone is insufficient for protocol evaluation because high viability may occur with low live-cell recovery, so both viable percentage and absolute live-cell recovery should be measured after thawing.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)